for the GENOMOS Study
teoporotic fractures are for the most part unknown, it is thought that the risk of developing osteoporosis is dependent on several common gene variants, each with modest effects. 3, 4 During recent years, variation in the gene coding for low-density lipoprotein receptor-related protein 5 (LRP5) has been implicated in bone mass accrual and susceptibility to osteoporosis. LRP5, and itscloselyrelatedhomologue,LRP6,functionascell-membranecoreceptorsforWnt proteins in the canonical Wnt signaling pathway. 5, 6 Several lines of evidence suggest that LRP5 may be a key determinant of bone mass. Loss-of-function mutations in the LRP5 gene cause osteoporosispseudoglioma syndrome, 6 characterized by severe osteoporosis and blindness. Conversely, activating point mutations in this same gene result in high bone mass. 7, 8 OtherLRP5missensemutationshavebeen described in patients with bone mass disorders, including endosteal hyperostosis, osteopetrosis, and osteosclerosis. 9 Variousmousemodelshavealsoreplicatedthe bone phenotype of mutated LRP5. 6, 10 Common genetic variations in LRP5 have been proposed as candidates for influencing bone phenotypes at the population level. Some reports have suggested that LRP5 polymorphisms contribute to variation in BMD in the general population, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] but results are inconclusive. This inconsistency can be explained in part by variations in the examined polymorphisms, the analytical approaches used, and the examined phenotypes. Data on fracture risk are limited, with only 2 reports published so far. 14, 22 The most frequently studied polymorphisms in this gene are 2 amino acid substitutions (Val667Met and Ala1330Val), 13, 15, 17, 18, [21] [22] [23] [24] [25] and there is some additional in vitro evidence that the Ala1330Val variant results in a functional difference of the LRP5 protein. 25 Mouse studies have shown that point mutations in the LRP6 gene lead to a low bone mass phenotype. 26 While LRP6deficient mice have early developmental problems that are not compatible with life, mice that carry (heterozygous) mutations in both LRP5 and LRP6 have decreased BMD and limb deformities, which indicates that LRP5 and LRP6 interact in limb development and BMD acquisition. 27 A recent report has identified an inherited mutation in LRP6 to be linked to coronary heart disease but also to low-trauma fractures and low BMD. 28 In addition, a common protein variant of LRP6 (Ile1062Val) has been found to contribute to fracture risk in elderly men. 22 This same variant was recently shown to have functional consequences in vitro 29 .
The objective of the current study was to examine the contribution of 2 common amino acid substitutions in the LRP5 protein and of 1 amino acid substitution in the LRP6 protein to BMD and risk of fracture using largescale evidence.
Some scattered studies [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] have tested this association, but results have not been conclusive due to limited sample size. The current collaborative study has the potential to answer this question more definitively because of its large sample size and therefore large power to observe the expected modest associations. In addition, its prospective design, consistent genotyping, and combined analysis of individual-level data diminish bias and the respective noise and heterogeneity that bias might introduce in the outcomes.
We report here on the combined analysis of individual-level data from the full Genetic Markers for Osteoporosis (GENOMOS) consortium, including data from 37 534 individuals. GENOMOS collected standardized data and performed prospective genotyping for these polymorphisms across a large number of teams, only a few of which had previously addressed some of these specific polymorphisms. 22, 23, 25, 30, 31 
METHODS

Organizational Issues
The GENOMOS project is a large-scale study of candidate gene polymorphisms for osteoporosis outcomes. 32 This report includes the 12 study populations included in previous collaborative analyses of other gene polymorphisms. [32] [33] [34] The decisiontostudytheLRP5andLRP6polymorphisms in the GENOMOS consor-tium occurred on June 6, 2004, when the consortium consisted of these 12 European populations. [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] At that time, results were available for 1 study (ERGO [Rotterdam, the Netherlands]), so all other populations were genotyped prospectively.Duringthecourseofthisstudy,participants from 6 other teams (4 from Europe, [45] [46] [47] [48] 1fromtheUnitedStates, 25 All studied individuals were white, and race/ethnicity was self-reported by study participants.
Details on the design of the 18 studies 25, 30, [35] [36] [37] [38] [39] [40] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] are provided in TABLE 1  and further details in TABLE 2 , eTable 1, and eTable 2. Participants were unrelated in all studies except FAMOS, for which we selected 1 participant per pedigree using random-number selection. Participating teams contributed information on LRP5 and LRP6 genotypes, sex, age, height, weight, menopausal status, use of hormone therapy, activity and ability data (when available), BMD at lumbar spine and femoral neck (in mg/cm 2 ), and fractures. Bisphosphonate use was very rare and thus was not believed to warrant a separate analysis (although available data are reported herein). Smoking status and exercise were not collected in the same format across cohorts. Nevertheless, exercise and ability-adjusted estimates of effect in single studies were obtained whenever possible. The coding of smoking was heterogeneous; thus, as opposed to exercise and ability data, for which the scales were simply different, the smoking categories in each co-hort may be overlapping or inconsistent. Therefore, it was believed that adjustment for smoking could not provide meaningful results (although available data are reported herein). For all analyses, participants with missing relevant data were excluded.
This study was approved by the institutional review boards of each local institution, and all individuals provided written informed consent to participate in clinical and genetic studies.
BMD Measurements
Bone mineral density was measured by dual-energy x-ray absorptiometry with different devices (Table 1) . Measurements used the same reference device within each population. We interpreted results of the analysis of individual-level data for BMD by comparing within-population absolute differences in the mean values of BMD across genotypes. We do not focus on absolute BMD values, because these val-ues may depend on the measuring device.
Fracture Assessment
Fractures were identified either by questionnaire, medical records, or radiographic documentation. Details of fracture assessment and exclusion of age at fracture, fracture type, and trauma type for each cohort are given in Table 2 . Longitudinal studies also had data available on incident fractures that had occurred during the follow-up period. Information on incident vertebral fractures included in the analysis was collected with routine surveillance methods using radiographic examination.
Genotyping
We genotyped LRP5 Val667Met (dbSNP [http://www.ncbi.nlm.nih.gov/projects /SNP/] ID rs4988321), LRP5 Ala1330Val (rs3736228), and LRP6 Ile1062Val (rs2302685) single-nucleotide polymorphisms (SNPs) prospectively. These 3 SNPs were the only ones examined in this study. LRP5 Val667Met (rs4988321), LRP5 Ala1330Val (rs3736228), and LRP6 Ile1062Val (rs2302685) polymorphisms were assessed by Taqman, except for the AOS study, for which fluorescence polarization was used for assessment of the LRP5 Val667Met and LRP6 Ile1062Val polymorphisms. We cross-validated genotypes from different laboratories by blinded genotyping of 50 reference samples by all genotyping teams. The coordinating team in Rotterdam evaluated the results and reported any discrepancies in the reference samples in general terms to improve calling of genotypes by failing teams. We repeated genotyping of the reference samples, and teams had to switch genotyping techniques if they were still generating more than 5% errors in the reference samples. In addition, each team checked its own cohort genotyping afterward by reanalyzing at least 5% of their samples selected at random. Genotyp- ing was performed after all prospective radiographic measurements had been performed and had been entered into the databases, so assessment of whether or not a fracture existed would not have been affected by knowledge of genotype.
Outcomes
The main outcomes included BMD of the lumbar spine and femoral neck; all prevalent fractures; and prevalent vertebral fractures by clinical or morphometric criteria. 53 We also conducted sensitiv-ityanalysesforincidentfractures;incident vertebral fractures; and low-and notrauma fractures. The latter exclude fractures occurring with high trauma, as assessedbythecircumstancesinwhichthey had occurred, their location, or both. Information on high-and low-trauma fractures was available for 6 of the 18 studies.
Analyses
Hardy-Weinberg Equilibrium and Haplotype Reconstruction. We performed exact tests for Hardy-Wein-berg equilibrium proportions 54 using GENEPOP version 4.0. 55 We reconstructed haplotypes of the 2 LRP5 polymorphisms using PHASE version 2.0. 56 Evaluation of Genetic Effects. All analyses were stratified per study and sex (29 study-sex population strata). For single-SNP analyses we obtained summary estimates using inverse-variance random-effects metaanalysis. For haplotype-based analyses we used mixed models, as described below. 
Inverse-Variance Random-Effects Analyses of Individual-Level Data (Single-SNP-Based Analyses)
. This is a 2-step approach. Separate regression models were performed in each study-sex population stratum (genetic information was coded using dummy variables, depending on the genetic model assessed). We calculated summary genetic effect as the weighted average of regression coefficients across the different strata using the DerSimonian and Laird random-effects method. 5 7 This method allows for between-strata heterogeneity (dissimilarity) and incorporates it in the calculations. We tested for heterogeneity using the Cochran Q statistic (traditionally considered statistically significant at P Ͻ .10) 58 and quantified its extent using the I 2 statistic (large heterogeneity for values Ն50%). 59 Results of single-SNP-based analyses with mixed models were identical and thus not shown.
Mixed Models (Haplotype-Based Analyses). Linear mixed models were used for continuous outcomes (ie, BMD measurements), and the corresponding generalized linear mixed models were used for binary outcomes (eg, fractures). Population stratum was treated as a random factor and genetic information (haplotypes) as fixed. All models were fitted using maximum likelihood. We relied on a likelihood ratio test to assess whether a model taking into account the genetic information provided better fit (ie, explained data better) than a similar model without the genetic information (eg, a constantonly model).
Choice of Genetic Model and Adjustments. Since there is no strong evidence in favor of a specific genetic model, main analyses used allelebased contrasts. Additional analyses assumed a dominant model for continuous as well as binary outcomes and a "model-free" approach that considers the 3 genotypes as independent factors. For analysis of incident fractures, the binary variable "fracture: yes/ no" was used, and odds ratios (ORs) were calculated and translated into risk ratios (RRs) as described below. There would be no rationale for longitudinal time-to-event analyses (eg, a vertebral fracture identified on a radiograph may have occurred at any point in the period between enrollment and follow-up radiography).
The main analyses were unadjusted for other variables. We also performed secondary adjusted analyses by accounting for age, weight, and height (as continuous variables) in the models. Whenever statistically significant genetic effects were identified, additional adjustments for postmenopausal status and use of hormone therapy among women were undertaken. Fracture-risk analyses were also adjusted for BMD (lumbar spine BMD or femoral neck BMD in separate analyses). The proportion of the fracture risk explained by BMD was calculated from the regression coefficients as (␤ unadjusted − ␤ adjusted )/␤ unadjusted .
In additional analyses, we tested for interactions of the 2 LRP5 SNPs with age (among all individuals) and postmenopausal status (among women).
Effects at the Population Level. For an indicative population-level estimate, the per-allele OR for the significant associations with fractures and vertebral fractures was also converted into an RR 60 considering the median fracture prevalence across the included cohort studies. We calculated the populationattributable fraction using allele frequencies from the median cohort study.
Adjustments for Multiple Comparisons
Adjustment for multiple comparisons is generally not favored for hypothesisvalidating studies as opposed to discovery studies. Nevertheless, we have illustratively also adjusted the main estimates for the main analyses for 3 polymorphisms ϫ4 main outcomes (lumbar spine BMD, femoral neck BMD, all fractures, and vertebral fractures) using the Boole-Bonferroni inequality. 61 We emphasize that because the 4 main outcomes are correlated and 2 of 3 polymorphisms are also in linkage disequi-librium, Bonferroni adjustments are overly conservative. Conventional statistical significance is claimed for PϽ.05 adjusted for multiple comparisons. Genome-wide significance is claimed for unadjusted P Ͻ 10 −7 . [62] [63] [64] Genomewide significance accounts for the very large number of polymorphisms and associations thereof that can be tested across the human genome, regardless of whether all or some of them are tested in a study.
Our study is more than 90% powered to detect effect sizes of 0.1 SD in BMD and ORs of 1.20 for fractures and vertebral fractures, if the associations are consistent across different populations. Power would be eroded in the presence of large between-population heterogeneity. 65 All statistical analyses were performed using Intercooled Stata 8. 
RESULTS
Database
Data were collected between September 2004 and January 2007. Analysis of the collected data was performed between February and May 2007. Among the 37 534 participants (24 177 women) analyzed, data on lumbar spine BMD, femoral neck BMD, all fractures, and vertebral fractures existed for 28 073, 28 022, 35 762, and 22 580 participants, respectively. There were 8932 participants with any fracture and 2146 with vertebral fractures. Basic characteristics and further details of the cohorts are shown in Tables 1 and 2 and eTables 1 and 2. Genotypic information on LRP5 Val667Met, LRP5 Ala1330Val, and LRP6 Ile1062Val was available for 32 720, 32 423, and 33 038 individuals, respectively. Information on all 3 SNPs was available for 30 989 individuals. The eFigure shows the position of the SNPs in the gene with the haplotypes and its frequencies in the total population studied. The frequency of the Met667 allele ranged from 2% to 8%, of Val1330 from 10% to 19%, and of LRP6 Val 1062 from 15% to 23% (for details see eTable 3).
Genotype frequencies were similar across the participating populations (eTable 3). No data set deviated signifi-cantlyfromHardy-Weinbergequilibrium (PϾ.05), except for LRP6 Ile1062Val (in AOS and APOSS) and LRP5 Ala1330Val (in FLOS and LASA). Exclusion of these data did not affect summary estimates or conclusions(notshown).Linkagedisequi-libriumbetweentheLRP5polymorphisms was consistently high across all studies (D'Ͼ0.85), which allowed inference of haplotypes with high confidence for all cohorts. We consistently identified 3 ma-jorhaplotypes,andhaplotypefrequencies were similar across cohorts (eTable 3).
BMD Analyses
Effects of LRP5 Met667 and Val1330.
For the LRP5 Val667Met and Ala1330Val polymorphisms, highly significant effects on the lumbar spine and femoral neck BMD were observed (TABLE 3) . The BMD effects tended to be larger for Val667Met than for Ala1330Val. The largest effects were found for lumbar spine BMD, which decreasedby20mg/cm 2 (n=25 052[number of participants with available data]; P=3.3ϫ10 −8 ) per copy of Met667 allele and14mg/cm 2 (n=24 812;P=2.6ϫ10 −9 ) per copy of Val1330 allele. For the fem-oral neck, the effects were 11 mg/cm 2 (n=25 193; P=3.8ϫ10 −5 ) and 8 mg/cm 2 (n=25 026; P=5.0ϫ10 −6 ), respectively. The aforementioned results remained significant after adjusting for multiple comparisons (the adjusted P values were 4.0ϫ10 −7 , 3.1ϫ10 −8 , 4.6ϫ10 −4 , and 6.0ϫ10 −5 , respectively).
Findings were highly consistent across studies for both LRP5 variants (FIGURE 1  and FIGURE 2) , and no heterogeneity was detected (P for heterogeneity Ͼ.90 for all analyses). Adjustment of the estimates for age, height, and weight and further adjustment for postmenopausal status and use of hormone therapy in women had no major effect on the associations (eTable 4). Teams used very different scales to measure activity or ability as shown in eTable 1, but stratum-specific adjustments using mean-centered scores did not appreciably alter the within-strata estimates of the genetic effects (P Ͼ.10 by likelihood ratio test compared with corresponding models without the exercise and ability information). We could not detect a sex difference in the association between LRP5 variants and BMD, but modest sex-specific associations cannot be excluded. LRP5 haplotypes were highly significantly associated with lumbar spine BMD and femoral neck BMD overall (P = 9.3ϫ10 −10 and P =8.4ϫ 10 −6 , likelihood ratio tests vs similar models without the LRP5 haplotypes). Using haplotype 1 (Val667-Ala1330) as a reference, each copy of haplotype 2 (Val667-Val1330) and haplotype 3 (Met667-Val1330) was associated with a lower lumbar spine BMD of 10 mg/ cm 2 (P = 3.6 ϫ 10 −4 ) and 21 mg/cm 2 (P = 1.7ϫ 10 −8 ), respectively ( Table 3) . The corresponding decreases in femoral neck BMD were 6 mg/cm 2 (P=.003) and 13 mg/cm 2 (P =5.8ϫ 10 −6 ).
Effects of LRP6 Val1062. The Ile1062Val polymorphism of LRP6 did not show a significant association with BMD ( Table 3 and Figures 1 and 2) . No significant between-study heterogeneity was detected (PϾ.57 for all analyses). Adjusted analyses showed similar results (eTable 4). There was no significant interaction between the LRP5 haplotypes and the LRP6 Ile1062Val polymorphism on BMD based on likelihood ratio tests vs similar mixed models without the interaction terms.
Fracture Analyses. Effects of LRP5 Met667 and Val1330. Both LRP5 variants were significantly associated with fracture risk (FIGURE 3, FIGURE 4, and  TABLE 4 ). For each Met667 allele, the odds for any prevalent fracture in- P=.03) . The effects were no longer significant after adjustments for multiple comparisons (adjusted P values became .30 and .31, respectively).
The median prevalence of all fractures and vertebral fractures among cohort studies was 27% and 2.7%, respectively. The calculated RRs for each copy of the Met667 allele on the population level were 1.10 and 1.25 for all fractures and vertebral fractures, respectively. The corresponding RRs for the Val1330 allele were 1.12 and 1.04. The population-attributable risk for both Val1330 and Met667 was approximately 1% for fractures and 3% for vertebral fractures.
Excluding patients with vertebral fractures, the per-allele ORs for nonvertebral fractures were found to be 1.12 (95% CI, 1.02-1.23) and 1.05 (95% CI, 0.99-1.12) for the LRP5 Met667 and LRP5 Val1330 alleles, respectively. Effects on fractures were unaltered when adjustments were made for age, weight, height, and postmenopausal status; no 
Ala1330Val
Results based on inverse-variance random-effects analysis of individual-level data. The size of the data markers is proportional to the weight (inverse of the variance) of each study. AUSTRIOS-B did not have available data on bone mineral density measurements and therefore is not included in this analysis. BMD indicates bone mineral density; CI, confidence interval. Estimates for UFO (men) could not be obtained for LRP5 Val667Met and LRP6 Ile1062Val because all analyzed individuals had the same genotype.
between-study heterogeneity was detected (PϾ .33 for all analyses). When adjustments for each individual's BMD were performed at either the lumbar spine or femoral neck, the formal significance of the overall effects on fracture was lost for most of the associations. The effect of the Val1330 allele on all fractures was unaltered by adjustment with lumbar spine BMD, while approximately 30% of the increased risk for vertebral fractures conferred by the LRP5 Met667and LRP5 Val1330 alleles was explained by the lumbar spine BMD. Similarly, lumbar spine BMD explained approximately one-third of the effect of the Met667 allele on risk of all fractures and vertebral fractures (see also eTable 5).
Overall, LRP5 haplotypes were marginally associated with the risk for all fractures (P =.05; likelihood ratio test) and with the risk for vertebral fractures (P = .02; likelihood ratio test) ( Table 4 ). Using the most common haplotype (haplotype 1, Val667-Ala1330) as reference, carriage of each copy of haplotype 3 (Met667-Val1330) was associated with an increase in the odds for vertebral fractures of 28% (95% CI, 1.08-1.55; P =.006). Associations with any prevalent fracture were not beyond what would be expected by chance.
Effects of LRP6 Val 1062 . The LRP6 Ile1062Val polymorphism was not associated with fractures overall ( Table 4 ). The CIs excluded 6% differences in the OR for any prevalent fracture between alleles. Adjustment for age (as well as sex, weight, and height) did not appreciably change any of the summary estimates for fracture risk. There was no significant heterogeneity between studies in any analysis. eTable 6 depicts analyses for incident and low-energy fractures. Results were not conclusive, given the availability of much more limited data.
Sensitivity and Interaction Analyses. There was no evidence for a statisti- 
Odds Ratio (95% CI)
Results based on inverse-variance random-effects analysis of individual-level data. Summary estimates of the odds ratios and their 95% confidence intervals (CIs) are given. The size of the data markers is proportional to the weight (inverse of the variance) of each study. AOS did not have available data on any fracture and therefore is not included in this analysis. 
Results based on inverse-variance random-effects analysis of individual-level data. Summary estimates of the odds ratios and their 95% confidence intervals (CIs) are given. The size of the data markers is proportional to the weight (inverse of the variance) of each study. AOS, FOS, GOOD, MrOS, and UFO did not have available data on vertebral fracture and therefore are not included in this analysis. cally significant interaction of the LRP5 variants with age for lumbar spine BMD, femoral neck BMD, any prevalent fracture, and any prevalent vertebral fracture. The same was true when interactions with menopausal status were assessed, with a single exception: each copy of the Val1330 allele was associated with an approximately 18-mg/cm 2 decrease in femoral neck BMD among premenopausal women but with only a 4-mg/cm 2 decrease among postmenopausal women (P=.007 for the Val1330 by menopausal status interaction).
COMMENT
In this large-scale multicenter collaborative study, we obtained evidence that genetic variation of the LRP5 gene is associated with both BMD and fracture risk. The magnitude of the effects was modest but very consistent across studies. The effect size was 14 to 20 mg/ cm 2 for lumbar spine and 8 to 11 mg/ cm 2 at the femoral neck, which approximately corresponds to a 0.15-SD difference at both sites. Based on the general acceptance that a 1-SD reduction in bone mass doubles the fracture rate, 66 an increase of fracture risk of about 15% to 20% is expected. This is similar to the observed effects on fracture, although adjustment for BMD only partly reduced the increase in fracture risk. This could raise the possibility of effects on bone quality, bone dimension, or other nonskeletal determinants of fracture, but also could be due to error in measurement of BMD. Further work will be required to address this point. Several previous reports have suggested that the association between genetic variation of the LRP5 gene and BMD might be stronger in men compared with women. 22, 25 We could not find such a sex difference. In fact, for fractures we found a slightly stronger effect for women as compared with men, although power was lower to detect effects for men.
LRP5 may be involved in the establishment of peak bone mass 6 and to a lesser extent involved in bone loss. Bone mineral density is substantially af-fected by age-related bone loss at older ages, so differences in BMD between LRP5 genotype groups might become smaller with age. 25 In our study there was no clear influence of age on the magnitude of the association between LRP5 variants and BMD or fracture. For femoral neck BMD, differences between the Ala1330Val genotypes were larger in premenopausal women compared with postmenopausal women, which could indicate that the effect of LRP5 variants is largely seen on peak bone mass. However, this was not observed for lumbar spine BMD and the Ala1330Val variant or with the Val667Met polymorphism for any of the outcomes. Even with such large-scale evidence, the presence or absence of interaction effects should be interpreted very cautiously.
The 2 polymorphisms in LRP5 are each strongly associated with BMD. Although these polymorphisms are in strong linkage disequilibrium, the risk alleles were separated in 2 haplotypes: haplotype 2, carrying the common Val667 and the Val1330 risk allele, and haplotype 3, carrying risk alleles for both Met667 and Val1330. Haplotypes 2 and 3 were both associated with BMD while haplotype 3 was more strongly associated, which suggests that both variants have distinct effects. However, we cannot exclude that the polymorphisms are in linkage disequilibrium with 1 or more other causative polymorphisms rather than having an effect themselves.
The 2 studied LRP5 variants are situated in different domains of the protein. The Val667Met polymorphism is localized at the top of the third propeller module in the receptor extracellular domain. This domain is thought to be involved in binding of the Wntinhibitor Dkk1, so perhaps binding efficacy of this inhibitor is changed in the Met667 variant. The Ala1330Val polymorphism lies within a second lowdensity lipoprotein (LDL) receptor domain of LRP5. The function of this region in LRP5 is unknown, but similar domains in the LDL receptor domain interact with the propeller do-mains. 67 Therefore, variations in the LDL receptor domains, such as Ala1330Val, may still alter protein function. Indeed, a recent report showed in vitro that Wnt-signaling capacity of the LRP5 Val1330 variant was decreased compared to the Ala1330 variant. 25 The strengths of our consortium analysis include the very large sample size, consistency across cohorts, lack of publication bias within the consortium due to its prospective design, and analysis of individual-level data, which allows standardized statistical analyses across participating teams.
In particular, we focused on validation of genotyping to minimize genotyping errors and aimed at standardized definitions for the outcomes. Limitations arise due to ascertainment of fractures, which differed across participating studies. This could introduce some unavoidable heterogeneity in the analyses. Another potential limitation is due to missing data in some cohorts. In addition, our results might not pertain to Asian and/or African populations, since we only examined white populations.
Our findings demonstrate that the modest effects of common genetic variations in complex diseases can be effectively addressed through large consortia and coordinated, standardized analysis. Such effects might be missed by smaller and potentially underpowered individual studies. This prospective collaborative study with individual level-data of 37 534 participants shows an effect of LRP5 genetic variation on both BMD and risk of fracture. While some other common variants have been associated previously with osteoporosis phenotypes with large-scale evidence, [17] [18] [19] this may be the first time that an association in this field crosses the threshold of genome-wide statistical significance (P Ͻ 10 −7 ). Given the large number of polymorphisms that can be tested in the human genome, it has been argued that to fully account for all these possible comparisons (regardless of whether all of them are made), a very conservative threshold is needed. [62] [63] [64] Although the magnitude of the effect was modest, the effect was very consistent in different populations and independent of sex or age. This suggests a role for LRP5 in determining BMD and fracture risk throughout life in the general population. Although any single marker explains only a small portion of the phenotype risk, identification of several such osteoporosis risk variants may eventually help in improving clinical prediction. Single genetic risk variants such as LRP5 variants may also offer useful insights about mechanisms and pathways that may be useful in drug development.
